Clazakizumab was found to be well tolerated, with potential safety concerns related to serious infections and elevated cholesterol levels. Patients experienced significant increases in albumin levels, which is a positive indicator for improved outcomes in individuals receiving dialysis. This treatment shows promise in reducing inflammatory markers and potentially reducing cardiovascular risk in dialysis patients. Additionally, a study comparing home hemodialysis and peritoneal dialysis found lower rates of cardiovascular events and mortality in patients undergoing home hemodialysis. Further research is needed to explore the differences in outcomes between these two dialysis modalities. These findings highlight the potential benefits of targeted anti-inflammatory treatments for dialysis patients.
Source link
How Can Cardiovascular Risk Be Reduced in Kidney Dialysis?
